Diabesity Effects on Fetuin- A, Adiponectin and Leptin
Keywords:
obesity, fetuin-A, leptin, adiponectin, diabetes
Abstract
An increasing amount of epidemiological research connects liver function to excessive weight and its aftereffects, that also diabetes and metabolic illness. Experiments showed a elaborate system of connections in relation to liver and fat storage that mutually regulate their respective activities, in line with human findings. The main mediators of this connection are hormone/cytokine signals located in the fat (adiponectin and leptin) and the liver (fetuin-A). We will discuss the latest advancements in our comprehension of the processes underpinning the interaction in relation to the liver and adipose tissue that puts individuals at risk for diabetes, obesity, and other health problems. Increased fetuin-A degrees are link to grow likelihood of developing type two diabetes and the metabolic illness. Adiponectin deficiency is associated with multiple illnesses, that also atherosclerosis, type 2 diabetes as well as body fat. Hyperglycemia and hyperinsulinemia, which result from inadequate leptin signaling in the hypothalamus (produced by hyperleptinemia in obese individuals), are the primary causes of diabetes mellitus.
References
“Obesity fact sheet,” World Obesity Day 2022.
E. A. H. Sims, E. D. Jr, E. S. Horton, G. A. Bray, and ..., “Endocrine and metabolic effects of experimental obesity in man,” Proceedings of the 1972 …, 1973, [Online]. Available: https://www.sciencedirect.com/science/article/pii/B9780125711296500166
J. M. Pappachan, C. J. Fernandez, and E. C. Chacko, “Diabesity and antidiabetic drugs,” Mol Aspects Med, 2019, [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0098299718300840
“Nonalcoholic Fatty Liver Disease (NAFLD),” American Liver Foundation. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld. Accessed May 11, 2023.
G. Ren, T. Kim, J. B. Papizan, and ..., “Phosphorylation status of fetuin-A is critical for inhibition of insulin action and is correlated with obesity and insulin resistance,” … Journal of …, 2019, doi: 10.1152/ajpendo.00089.2018.
T. M. D. Nguyen, “Adiponectin: role in physiology and pathophysiology,” Int J Prev Med, 2020, [Online]. Available: https://journals.lww.com/ijom/fulltext/2020/11000/Adiponectin__Role_in_Physiology_and.9.aspx
H. T. Idriss and J. H. Naismith, “TNF alpha and the TNF receptor superfamily: structure-function relationship (s) Microsc Res Tech. 2000; 50 (3): 184–195. doi: 10.1002/1097-0029 …,” Co.
S. Dornbush and N. R. Aeddula, Physiology, leptin. europepmc.org, 2019. [Online]. Available: https://europepmc.org/article/nbk/nbk537038
V. Y. Guo, B. Cao, C. Cai, K. K. Cheng, and B. M. Y. Cheung, “Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis,” Acta Diabetol, 2018, doi: 10.1007/s00592-017-1068-9.
N. Stefan, A. Fritsche, C. Weikert, H. Boeing, H. G. Joost, and ..., “Plasma fetuin-A levels and the risk of type 2 diabetes,” Diabetes, 2008, [Online]. Available: https://diabetesjournals.org/diabetes/article-abstract/57/10/2762/13362
J. F. Trepanowski, J. Mey, and K. A. Varady, “Fetuin-A: a novel link between obesity and related complications,” Int J Obes, 2015, [Online]. Available: https://www.nature.com/articles/ijo2014203
M. Howlader, M. I. Sultana, F. Akter, and M. M. Hossain, “Adiponectin gene polymorphisms associated with diabetes mellitus: A descriptive review,” Heliyon, 2021, [Online]. Available: https://www.cell.com/heliyon/pdf/S2405-8440(21)01954-X.pdf
A. Engin, “Adiponectin-resistance in obesity,” Obesity and lipotoxicity, 2017, doi: 10.1007/978-3-319-48382-5_18.
R. Ambad, R. K. Jha, D. H. Chandi, and ..., “Association of leptin in diabetes mellitus and obesity,” Research Journal of …, 2020, [Online]. Available: https://www.indianjournals.com/ijor.aspx?target=ijor:rjpt&volume=13&issue=12&article=110
M. Obradovic, E. Sudar-Milovanovic, S. Soskic, and ..., “Leptin and obesity: role and clinical implication,” Frontiers in …, 2021, doi: 10.3389/fendo.2021.585887.
A. M. Hennige, H. Staiger, C. Wicke, F. Machicao, and ..., “Fetuin-A induces cytokine expression and suppresses adiponectin production,” PLoS One, 2008, [Online]. Available: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001765
A. G. Tabák, M. Carstensen, D. R. Witte, E. J. Brunner, and ..., “Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study,” Diabetes …, 2012, [Online]. Available: https://diabetesjournals.org/care/article-abstract/35/12/2540/38570
A. E. Achari and S. K. Jain, “Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction,” Int J Mol Sci, 2017, [Online]. Available: https://www.mdpi.com/1422-0067/18/6/1321
R. Coppari and C. Bjørbæk, “Leptin revisited: its mechanism of action and potential for treating diabetes,” Nat Rev Drug Discov, 2012, [Online]. Available: https://www.nature.com/articles/nrd3757
S. Klein, A. Gastaldelli, H. Yki-Järvinen, and P. E. Scherer, “Why does obesity cause diabetes?,” Cell Metab, 2022, [Online]. Available: https://www.cell.com/cell-metabolism/pdf/S1550-4131(21)00631-8.pdf
A. E. Achari and S. K. Jain, “Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction,” Int J Mol Sci, 2017, [Online]. Available: https://www.mdpi.com/1422-0067/18/6/1321
E. A. H. Sims, E. D. Jr, E. S. Horton, G. A. Bray, and ..., “Endocrine and metabolic effects of experimental obesity in man,” Proceedings of the 1972 …, 1973, [Online]. Available: https://www.sciencedirect.com/science/article/pii/B9780125711296500166
J. M. Pappachan, C. J. Fernandez, and E. C. Chacko, “Diabesity and antidiabetic drugs,” Mol Aspects Med, 2019, [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0098299718300840
“Nonalcoholic Fatty Liver Disease (NAFLD),” American Liver Foundation. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld. Accessed May 11, 2023.
G. Ren, T. Kim, J. B. Papizan, and ..., “Phosphorylation status of fetuin-A is critical for inhibition of insulin action and is correlated with obesity and insulin resistance,” … Journal of …, 2019, doi: 10.1152/ajpendo.00089.2018.
T. M. D. Nguyen, “Adiponectin: role in physiology and pathophysiology,” Int J Prev Med, 2020, [Online]. Available: https://journals.lww.com/ijom/fulltext/2020/11000/Adiponectin__Role_in_Physiology_and.9.aspx
H. T. Idriss and J. H. Naismith, “TNF alpha and the TNF receptor superfamily: structure-function relationship (s) Microsc Res Tech. 2000; 50 (3): 184–195. doi: 10.1002/1097-0029 …,” Co.
S. Dornbush and N. R. Aeddula, Physiology, leptin. europepmc.org, 2019. [Online]. Available: https://europepmc.org/article/nbk/nbk537038
V. Y. Guo, B. Cao, C. Cai, K. K. Cheng, and B. M. Y. Cheung, “Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis,” Acta Diabetol, 2018, doi: 10.1007/s00592-017-1068-9.
N. Stefan, A. Fritsche, C. Weikert, H. Boeing, H. G. Joost, and ..., “Plasma fetuin-A levels and the risk of type 2 diabetes,” Diabetes, 2008, [Online]. Available: https://diabetesjournals.org/diabetes/article-abstract/57/10/2762/13362
J. F. Trepanowski, J. Mey, and K. A. Varady, “Fetuin-A: a novel link between obesity and related complications,” Int J Obes, 2015, [Online]. Available: https://www.nature.com/articles/ijo2014203
M. Howlader, M. I. Sultana, F. Akter, and M. M. Hossain, “Adiponectin gene polymorphisms associated with diabetes mellitus: A descriptive review,” Heliyon, 2021, [Online]. Available: https://www.cell.com/heliyon/pdf/S2405-8440(21)01954-X.pdf
A. Engin, “Adiponectin-resistance in obesity,” Obesity and lipotoxicity, 2017, doi: 10.1007/978-3-319-48382-5_18.
R. Ambad, R. K. Jha, D. H. Chandi, and ..., “Association of leptin in diabetes mellitus and obesity,” Research Journal of …, 2020, [Online]. Available: https://www.indianjournals.com/ijor.aspx?target=ijor:rjpt&volume=13&issue=12&article=110
M. Obradovic, E. Sudar-Milovanovic, S. Soskic, and ..., “Leptin and obesity: role and clinical implication,” Frontiers in …, 2021, doi: 10.3389/fendo.2021.585887.
A. M. Hennige, H. Staiger, C. Wicke, F. Machicao, and ..., “Fetuin-A induces cytokine expression and suppresses adiponectin production,” PLoS One, 2008, [Online]. Available: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001765
A. G. Tabák, M. Carstensen, D. R. Witte, E. J. Brunner, and ..., “Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study,” Diabetes …, 2012, [Online]. Available: https://diabetesjournals.org/care/article-abstract/35/12/2540/38570
A. E. Achari and S. K. Jain, “Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction,” Int J Mol Sci, 2017, [Online]. Available: https://www.mdpi.com/1422-0067/18/6/1321
R. Coppari and C. Bjørbæk, “Leptin revisited: its mechanism of action and potential for treating diabetes,” Nat Rev Drug Discov, 2012, [Online]. Available: https://www.nature.com/articles/nrd3757
S. Klein, A. Gastaldelli, H. Yki-Järvinen, and P. E. Scherer, “Why does obesity cause diabetes?,” Cell Metab, 2022, [Online]. Available: https://www.cell.com/cell-metabolism/pdf/S1550-4131(21)00631-8.pdf
A. E. Achari and S. K. Jain, “Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction,” Int J Mol Sci, 2017, [Online]. Available: https://www.mdpi.com/1422-0067/18/6/1321
Published
2024-04-24
How to Cite
Ibrahim, N. A. K., Obeid, S. F., & Mohammad, W. J. (2024). Diabesity Effects on Fetuin- A, Adiponectin and Leptin. Central Asian Journal of Medical and Natural Science, 5(2), 166-171. https://doi.org/10.17605/cajmns.v5i2.2410
Issue
Section
Articles
